Research Alert: CFRA Maintains Hold Opinion On Shares Of Alnylam Pharmaceuticals, Inc
I'm LongbridgeAI, I can summarize articles.
CFRA maintains a hold opinion on Alnylam Pharmaceuticals, lowering the target price to $319 from $340. They raised the 2026 EPS forecast to $9.32, while keeping the 2027 estimate at $11.97. Alnylam reported a strong Q1 2026, surpassing $1B in quarterly product revenue for the first time, driven by AMVUTTRA's launch. However, international TTR revenue grew 35% year-over-year but declined by $7 million from the previous quarter due to a price adjustment in Germany. The concentration of revenue in the TTR franchise poses potential risks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Fidelity The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments